EP3585423A4 - Procédés et utilisations de l'alpha 1-antitrypsine pour une intervention précoce dans des maladies pulmonaires - Google Patents

Procédés et utilisations de l'alpha 1-antitrypsine pour une intervention précoce dans des maladies pulmonaires Download PDF

Info

Publication number
EP3585423A4
EP3585423A4 EP18758345.5A EP18758345A EP3585423A4 EP 3585423 A4 EP3585423 A4 EP 3585423A4 EP 18758345 A EP18758345 A EP 18758345A EP 3585423 A4 EP3585423 A4 EP 3585423A4
Authority
EP
European Patent Office
Prior art keywords
antitrypsin
alpha
methods
pulmonary diseases
early intervention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18758345.5A
Other languages
German (de)
English (en)
Other versions
EP3585423A1 (fr
Inventor
Tov NAVEH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kamada Ltd
Original Assignee
Kamada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kamada Ltd filed Critical Kamada Ltd
Publication of EP3585423A1 publication Critical patent/EP3585423A1/fr
Publication of EP3585423A4 publication Critical patent/EP3585423A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18758345.5A 2017-02-21 2018-02-21 Procédés et utilisations de l'alpha 1-antitrypsine pour une intervention précoce dans des maladies pulmonaires Pending EP3585423A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762461231P 2017-02-21 2017-02-21
PCT/IL2018/050194 WO2018154568A1 (fr) 2017-02-21 2018-02-21 Procédés et utilisations de l'alpha 1-antitrypsine pour une intervention précoce dans des maladies pulmonaires

Publications (2)

Publication Number Publication Date
EP3585423A1 EP3585423A1 (fr) 2020-01-01
EP3585423A4 true EP3585423A4 (fr) 2020-12-23

Family

ID=63253127

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18758345.5A Pending EP3585423A4 (fr) 2017-02-21 2018-02-21 Procédés et utilisations de l'alpha 1-antitrypsine pour une intervention précoce dans des maladies pulmonaires

Country Status (6)

Country Link
US (1) US10960062B2 (fr)
EP (1) EP3585423A4 (fr)
BR (1) BR112019017438A2 (fr)
CA (1) CA3054267A1 (fr)
IL (1) IL268752B2 (fr)
WO (1) WO2018154568A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3723790T3 (fi) * 2017-12-12 2024-04-19 Kamada Ltd Menetelmiä immuunitoleranssin indusoimiseksi ja lääkevasta-ainevasteen vähentämiseksi
WO2020157752A1 (fr) * 2019-01-29 2020-08-06 Kamada Ltd Composition d'aérosol pharmaceutique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL193319A (en) * 2006-02-09 2012-03-29 Shabtai Bauer Alpha-1 protein inhibitor for the treatment of exacerbations of lung disease
EP2740487A1 (fr) * 2006-02-09 2014-06-11 Kamada Ltd. Alpha-1-Antitrypsine pour le traitement des épisodes d'exacerbation des maladies pulmonaires
US20150011460A1 (en) * 2011-12-30 2015-01-08 Grifols, S.A. Alpha 1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE477817T1 (de) * 2000-06-27 2010-09-15 Novartis Vaccines & Diagnostic Nicht menschliche tiermodelle die toleranz gegenüber hepatitis c virus immunogene aufweisen
EP1664123B2 (fr) 2003-09-22 2011-11-30 Kamada Ltd. Preparation a grande echelle d'un inhibiteur d'alpha-1 proteinase et son utilisation
WO2005048985A2 (fr) * 2003-11-14 2005-06-02 Baxter International Inc. Compositions d'alpha 1-antitrypsine et procedes de traitement mettant en oeuvre de telles compositions
US9457070B2 (en) * 2005-06-07 2016-10-04 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
US9522179B2 (en) * 2010-03-04 2016-12-20 Virginia Commonwealth University Compositions and methods for modulating cardiac conditions
WO2012125487A1 (fr) * 2011-03-11 2012-09-20 Omni Bio Pharmaceutical, Inc. Compositions, procédés et utilisations d'agents radioprotecteurs
WO2012178102A2 (fr) * 2011-06-24 2012-12-27 The Regents Of The Unversity Of Colorado, A Body Corporate Compositions, procédés et utilisations de molécules de fusion de l'alpha-1 antitrypsine
EP3708182A1 (fr) * 2013-03-29 2020-09-16 The Regents Of The University Of Colorado Compositions et méthodes pour préparer un sujet à l'implantation d'un organe ou d'un non-organe
US20170239289A1 (en) * 2014-08-25 2017-08-24 Advanced Inhalation Therapies (Ait) Ltd. Treatment of inflammation, respiratory tract infections and cystic fibrosis
CA3040437A1 (fr) * 2016-10-13 2018-04-19 Kamada Ltd Regime posologique a variables multiples pour le traitement du diabete
CA3087421A1 (fr) * 2018-01-01 2019-07-04 Kamada Ltd. Methodes et compositions pour le traitement preventif de la maladie du greffon contre l'hote

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL193319A (en) * 2006-02-09 2012-03-29 Shabtai Bauer Alpha-1 protein inhibitor for the treatment of exacerbations of lung disease
EP2740487A1 (fr) * 2006-02-09 2014-06-11 Kamada Ltd. Alpha-1-Antitrypsine pour le traitement des épisodes d'exacerbation des maladies pulmonaires
US20150011460A1 (en) * 2011-12-30 2015-01-08 Grifols, S.A. Alpha 1-proteinase inhibitor for delaying the onset or progression of pulmonary exacerbations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUBBARD R C ET AL: "Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin", ANNALS OF INTERNAL MEDICIN, vol. 111, no. 3, 1 August 1989 (1989-08-01), AMERICAN COLLEGE OF PHYSICIANS, US, pages 206 - 212, XP009087767, ISSN: 0003-4819 *

Also Published As

Publication number Publication date
BR112019017438A2 (pt) 2020-05-05
US20200009234A1 (en) 2020-01-09
EP3585423A1 (fr) 2020-01-01
CA3054267A1 (fr) 2018-08-30
US10960062B2 (en) 2021-03-30
IL268752A (en) 2019-10-31
WO2018154568A1 (fr) 2018-08-30
IL268752B2 (en) 2024-01-01
IL268752B1 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
EP3515490B8 (fr) Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
EP3694529A4 (fr) Protéines trispécifiques et méthodes d'utilisation
EP3185900A4 (fr) Formulations de protéines d'oeuf et leurs procédés de fabrication
EP3177732A4 (fr) Compositions et procédés pour le traitement de maladies et états pathologiques ophthalmiques
EP3242672A4 (fr) Composition thérapeutique dérivée d'amnios et son procédé de production
EP3240799A4 (fr) Peptides hepcidine s-alkylés et leurs procédés de préparation et d'utilisation
EP3139866A4 (fr) Valvules cardiaques de remplacement, et leurs procédés d'utilisation et de fabrication
EP3274365A4 (fr) Isolat de protéine de maïs et procédés pour le produire
EP3238736A4 (fr) Peptide pour traiter des maladies oculaires et composition pour traiter des maladies oculaires comprenant celui-ci
EP3160493A4 (fr) Compositions et procédés pour réguler la rénalase dans le traitement de certaines maladies et de certains troubles
EP3247219A4 (fr) Produit protéique extrudé et procédés de production
EP3265096A4 (fr) Compositions ophtalmiques et leurs procédés d'utilisation
EP3151678A4 (fr) Compositions de protéines solubles et procédés pour les préparer
EP3148575A4 (fr) Méthodes et compositions de traitement d'allergie et les maladies inflammatoires
EP3136879A4 (fr) Compositions de protéines concentrées et procédés pour les préparer et les utiliser
EP3385273A4 (fr) Mutant de la protéine l1 du virus du papillome humain de type 58
EP3318275A4 (fr) Nouvel agent thérapeutique contre les maladies pulmonaires et/ou méthode de criblage de ces dernières
EP3456722A4 (fr) Formes cristallines de crisaborole sous forme libre et procédé de préparation et utilisation de celles-ci
EP3385274A4 (fr) Mutant de la protéine l1 du virus du papillome humain de type 11
EP3239149A4 (fr) Forme cristalline i de la canagliflozine et procédé de préparation de celle-ci
EP3419638A4 (fr) Compositions et procédés de traitement de maladies infectieuses chroniques
EP3488850A4 (fr) Nouvelle application de gzd824 dans le traitement de la leucémie lymphoblastique.
IL268752A (en) Methods and uses of alpha 1-antitrypsin for early intervention in lung diseases
EP3393460A4 (fr) Compositions et procédés de traitement de la miv et de maladies associées
EP3313427A4 (fr) Peptides thérapeutiques et leurs procédés d'utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190920

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0038570000

Ipc: A61K0038000000

A4 Supplementary search report drawn up and despatched

Effective date: 20201123

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101AFI20201117BHEP

Ipc: A61K 9/12 20060101ALI20201117BHEP

Ipc: A61K 9/72 20060101ALI20201117BHEP

Ipc: A61K 9/00 20060101ALI20201117BHEP

Ipc: A61K 38/57 20060101ALI20201117BHEP

Ipc: A61P 11/06 20060101ALI20201117BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230306

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230530